MedTrace Logo

Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies

NCT03447470 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-01-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety and tolerability of RXC004 as monotherapy and in combination with Nivolumab in patients with advanced malignancies. In order to define the doses and schedules for further clinical evaluation.

Conditions

Interventions

DRUG

RXC004

RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway.

DRUG

Nivolumab

RXC004 is taken orally, inhibits porcupine (PORCN) and interacts with the wnt signalling pathway. Nivolumab is a fully human monoclonal immunoglobulin G4 antibody to PD-1

Sponsors & Collaborators

  • Redx Pharma Ltd

    lead INDUSTRY

Principal Investigators

  • Natalie Cook · The Christie NHS Foundation Trust

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-18
Primary Completion
2023-09-29
Completion
2023-09-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03447470 on ClinicalTrials.gov